Author: admin (Donovan Greening)

Home / admin
5 Places Where You Can Find Asbestos in 2018
Post

5 Places Where You Can Find Asbestos in 2018

5 Places Where You Can Find Asbestos in 2018 Every year, deadly diseases produced by asbestos exposure such as mesothelioma and asbestosis are responsible for hundreds of deaths. For this reason, regular campaigns against mesothelioma are made, focusing on preventing asbestos exposure, banning it, enforcing regulations, and strengthening national and international partnerships. Speaking with a...

October 26, 2018October 26, 2018by
 Asbestos Popcorn Ceilings: Are they Safe?
Post

 Asbestos Popcorn Ceilings: Are they Safe?

So the big question, Asbestos Popcorn ceilings: Are they safe? Back in the 1950’s and 1980’s there was a special type of ceiling that was in the form of a spray on texture type; popcorn ceiling. This style made it easy for contractors to hide unwanted blemishes quickly. Sadly, during this time span there was...

August 10, 2018August 10, 2018by
Pleural Mesothelioma Symptoms to Look Out for
Post

Pleural Mesothelioma Symptoms to Look Out for

Pleural Mesothelioma Symptoms to Look Out for Mesothelioma cancer is not a normal or common illness. It is primarily a serious illness that is caused by asbestos exposure. Currently, there is no cure for this disease, yet specialists suggest that if earlier treatments start, there is a much better chance of an extended mesothelioma survival...

July 22, 2018July 22, 2018by
Malignant Pleural Mesothelioma
Post

Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma So, what is mesothelioma? Malignant pleural mesothelioma is a very aggressive and almost always fatal type of cancer caused by exposure to Asbestos. Approximately 3000 Americans are diagnosed with this terrible disease each year. Because malignant pleural mesothelioma is caused by exposure to Asbestos, it was believed that the occurrence of this disease...

October 12, 2017October 12, 2017by
Cell Medica to Manufacture WT1-TCR Therapy for Mesothelioma, Other Solid Tumors in 2018
Post

Cell Medica to Manufacture WT1-TCR Therapy for Mesothelioma, Other Solid Tumors in 2018

Cell Medica will begin manufacturing WT1-TCR cell therapy for solid tumors that have been difficult to treat with conventional therapies, such as mesothelioma and ovarian cancer. Cell Medica is planning to initiate a Phase 1/2 trial using a Dominant WT1-TCR version of the product in late 2018. WT1-TCR cell therapy involves taking a patient’s own immune cells...

June 28, 2017June 28, 2017by
Assessing Chemo and Immunotherapy Biomarkers at the Right Time Seen as Crucial in Mesotheliomia Monitoring
Post

Assessing Chemo and Immunotherapy Biomarkers at the Right Time Seen as Crucial in Mesotheliomia Monitoring

The point at which doctors assess biomarkers of mesothelioma patients’ response to a combination of chemotherapy and immunotherapy is crucial to obtaining a clear picture of how the patients are doing, a study reports. The same applies to other cancers, according to the study, which was published in BMC Cancer. A biomarker is a biological indicator of the...

June 28, 2017June 28, 2017by
Mesothelioma Risk Continues to Increase — 40 Years After Exposure
Post

Mesothelioma Risk Continues to Increase — 40 Years After Exposure

Even though 40 years have passed since their exposure to asbestos, workers’ risk of developing mesothelioma continues to rise, new research shows. Individuals exposed to asbestos four decades ago are nearly three times more likely to develop the disease than those exposed five years ago, a risk that surpasses even that seen in patients exposed 30 years ago. The...

June 28, 2017June 28, 2017by
Researchers Identify CXCR4 as Weak Therapeutic Target for Pleural Mesothelioma
Post

Researchers Identify CXCR4 as Weak Therapeutic Target for Pleural Mesothelioma

A new study reports that a protein formerly identified as a potential therapeutic target in pleural mesothelioma, CXCR4, might not be a relevant approach for the treatment of such patients. Based on this study’s results, researchers say that CXCR4 does not seem to be a promising therapeutic option for patients with progressive, inoperable or chemotherapy-resistant pleural mesothelioma. The study,...

June 28, 2017June 28, 2017by
PD-L1-positive Immune Cells May Help to Predict Survival Rates in EPMM, Study Says
Post

PD-L1-positive Immune Cells May Help to Predict Survival Rates in EPMM, Study Says

A study that looked into France’s RENAPE Observational Registry, a database of rare peritoneal tumors, found that the presence of programmed death-ligand 1 (PD-L1) on immune cells in epithelioid peritoneal malignant mesothelioma (EPMM) could help to predict overall and progression-free survival. Results of the study, “Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of...

June 28, 2017June 28, 2017by
Combining Immunotherapy, Accelerated Radiation and Surgery Bolsters Immune Response Against Mesothelioma, Study Shows
Post

Combining Immunotherapy, Accelerated Radiation and Surgery Bolsters Immune Response Against Mesothelioma, Study Shows

Combining immunotherapy, accelerated radiation and surgery can improve immune system response against malignant pleural mesothelioma, according to a study. Immunotherapies for solid tumors have become a major focus of cancer research, with promising preliminary results. But the advances have raised the question of what is the best way to integrate the new treatments with standard-of-care therapies....

June 28, 2017June 28, 2017by